GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (MEX:ATOS) » Definitions » Total Operating Expense

Atossa Therapeutics (MEX:ATOS) Total Operating Expense : MXN556.70 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Atossa Therapeutics Total Operating Expense?

Atossa Therapeutics's Total Operating Expense for the three months ended in Mar. 2025 was MXN151.68 Mil. Atossa Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was MXN556.70 Mil.

Atossa Therapeutics Total Operating Expense Historical Data

The historical data trend for Atossa Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Total Operating Expense Chart

Atossa Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 290.56 420.97 539.86 532.60 576.06

Atossa Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 115.84 130.16 125.72 149.14 151.68

Atossa Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN556.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (MEX:ATOS) » Definitions » Total Operating Expense
Comparable Companies
VXRT ACHV NMRA AGEN OBIO SGMT ASMB SAVA BDTX SGMO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ATOS:USA YAG2:Germany
Address
10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125
Website
https://www.atossatherapeutics.com
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.